Duloxetine Approved In EU For Stress Urinary Incontinence
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly and marketing partner Boehringer Ingelheim plan to launch duloxetine under the trade name Yentreve by year-end in the European Union. The NDA for Yentreve is pending at FDA.
You may also be interested in...
Lilly Cymbalta Clears FDA For Diabetes-Related Neuropathic Pain After Priority Review
Sales reps will start promoting the neuropathic pain indication to neurologists and pain specialists in the fourth quarter. After Lilly is confident duloxetine has been appropriately positioned as an antidepressant, a more active marketing of the neuropathic pain indication to primary care physicians will begin.
Lilly Cymbalta Clears FDA For Diabetes-Related Neuropathic Pain After Priority Review
Sales reps will start promoting the neuropathic pain indication to neurologists and pain specialists in the fourth quarter. After Lilly is confident duloxetine has been appropriately positioned as an antidepressant, a more active marketing of the neuropathic pain indication to primary care physicians will begin.
Cymbalta Approved; Lilly Antidepressant Will Be Available By Late August
Cymbalta (duloxetine) clears FDA for major depressive disorder after a lengthy review. It will be priced comparably to other antidepressants, including Wyeth's Effexor XR (venlafaxine), the other marketed selective serotonin/norepinephrine reuptake inhibitor.